Our findings disclosed that downregulation of the HLF gene was significantly associated with unfavorable OS outcomes in patients with CESC, HNSC, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, SARC, and UVM, and good OS outcomes of BLCA and READ patients. Here, HLF is linked to bladder transitional cell carcinoma.